Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719447 | 0.79 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL3464724 | 0.77 | L3MBTL1 (0.39) | DYRK1AL3MBTL1 | |
| SCHEMBL12121211 | 0.76 | DYRK1A (0.46) | DYRK1AL3MBTL1 | |
| SCHEMBL3465033 | 0.74 | DYRK1A (0.33) | DYRK1AL3MBTL1 | |
| SCHEMBL17305931 | 0.74 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL32683672 | 0.74 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL13755079 | 0.74 | P2RX7 (0.33) | DYRK1AL3MBTL1 | |
| SCHEMBL2875793 | 0.73 | ALOX15 (0.34) | DYRK1AL3MBTL1 | |
| SCHEMBL13748111 | 0.71 | DYRK1A (0.31) | DYRK1AL3MBTL1 | |
| SCHEMBL19661158 | 0.70 | DYRK1A (0.30) | DYRK1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| US-20240158408-A1 | Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof | 280 BIO, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024051784-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117683036-A | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-116262749-A | Aromatic heterocycle substituted compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-4166556-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-3119775-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140189-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| EP-2900654-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900657-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2040700-B1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009074519-A1 | COMBINATIONS OF PYRAZOLYL OR ISOXAZOLYL P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-2040700-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007141267-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066350-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATR, WEE1, WEE2 | DYRK1A 2194/4885L3MBTL1 2224/4885MAPT 3779/4885 |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | P2RX3, P2RX7, P2RX1 | DYRK1A 3671/4885L3MBTL1 4751/4885MAPT 740/4885 |
| US-20240158408-A1 | Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof | MTOR, AKT1, AKT2 | DYRK1A 2457/4885L3MBTL1 3011/4885MAPT 78/4885 |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | DYRK1A 2666/4885L3MBTL1 3408/4885MAPT 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.